间充质干细胞的免疫调节作用及临床经验
Immunomodulation by mesenchymal stem cells and clinical experience.
作者信息
Le Blanc K, Ringdén O
机构信息
Division of Clinical Immunology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
出版信息
J Intern Med. 2007 Nov;262(5):509-25. doi: 10.1111/j.1365-2796.2007.01844.x.
Mesenchymal stem cells (MSCs) from adult marrow can differentiate in vitro and in vivo into various cell types, such as bone, fat and cartilage. MSCs preferentially home to damaged tissue and may have therapeutic potential. In vitro data suggest that MSCs have low inherent immunogenicity as they induce little, if any, proliferation of allogeneic lymphocytes. Instead, MSCs appear to be immunosuppressive in vitro. They inhibit T-cell proliferation to alloantigens and mitogens and prevent the development of cytotoxic T-cells. In vivo, MSCs prolong skin allograft survival and have several immunomodulatory effects, which are presented and discussed in the present study. Possible clinical applications include therapy-resistant severe acute graft-versus-host disease, tissue repair, treatment of rejection of organ allografts and autoimmune disorders.
来自成人骨髓的间充质干细胞(MSCs)在体外和体内均可分化为多种细胞类型,如骨、脂肪和软骨。MSCs优先归巢至受损组织,可能具有治疗潜力。体外数据表明,MSCs固有免疫原性较低,因为它们几乎不会诱导同种异体淋巴细胞增殖(即便有,也极少)。相反,MSCs在体外似乎具有免疫抑制作用。它们抑制T细胞对同种异体抗原和丝裂原的增殖,并阻止细胞毒性T细胞的发育。在体内,MSCs可延长皮肤同种异体移植物的存活时间,并具有多种免疫调节作用。本研究将对此进行介绍和讨论。可能的临床应用包括治疗抵抗性严重急性移植物抗宿主病、组织修复、器官同种异体移植排斥反应的治疗以及自身免疫性疾病。